Please provide your email address to receive an email when new articles are posted on . A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic ...

Intraretinal hyperreflective foci, intraretinal hard exudates, and epiretinal membrane formation were lower after treatment with faricimab (Vabysmo) compared with aflibercept (Eylea) for patients with ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic diseases, today announced that it has completed ...

Returning from the 2024 American Academy of Ophthalmology Annual Meeting in Chicago, Dr Garg highlights several important studies on diabetic macular edema (DME). One key study focused on the ...

A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer comparable or improved anatomic and functional outcomes ...

Please provide your email address to receive an email when new articles are posted on . Examining the retina, particularly the macula, before cataract surgery is important to set appropriate patient ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

Eclipse Life Sciences begins phase 2 study for novel ophthalmology steroid implant for diabetic macular edema: Research Triangle Park, North Carolina Tuesday, April 14, 2026, 18:0 ...

MYL-1701P displayed similar efficacy, safety, and immunogenicity when compared with reference aflibercept to treat diabetic macular edema. Aflibercept is an intravitreal drug approved by the FDA for ...